Anticholinergic

By competing at muscarinic receptors, these agents reduce acetylcholine’s ability to produce parasympathetic responses. The resulting effects can include less smooth muscle contraction and glandular secretion, influencing the bronchi, intestine, bladder, and salivary glands. This receptor-level action explains why one drug class can affect several organ systems while producing both therapeutic effects and adverse reactions.

Acetylcholine contributes to smooth muscle activity, glandular secretion, and nerve signaling across multiple tissues. Reducing its muscarinic effects therefore changes more than one physiological function simultaneously. Bronchial constriction, intestinal motility, bladder contraction, and salivation may all decrease, so the clinical response reflects the distribution of parasympathetic activity rather than an effect limited to a single organ.

The desired response often comes from reducing a specific parasympathetic action, while unwanted reactions result when related functions are also reduced. Less bronchial constriction or bladder contraction may be beneficial, but diminished salivation, intestinal activity, or other parasympathetic effects can cause dry mouth, constipation, or urinary retention. Clinical use therefore requires balancing target effects against broader physiological consequences.

Adverse reactions such as confusion require particular attention in older adults, because the overview identifies this group as especially susceptible to clinically important effects. Assessment should therefore consider both the intended treatment response and symptoms such as dry mouth, blurred vision, constipation, urinary retention, or increased heart rate. This supports cautious balancing of benefit and tolerability.

In asthma and chronic obstructive pulmonary disease, the relevant therapeutic goal is reduced bronchial constriction. Blocking muscarinic effects can decrease this constrictive response, making the drug class useful for conditions in which airway narrowing is clinically important. The same treatment still requires attention to systemic adverse reactions, including dry mouth, blurred vision, increased heart rate, and confusion.

Its effects on smooth muscle provide a rationale for use in overactive bladder and gastrointestinal spasms. Reduced bladder contraction can address excessive bladder activity, while decreased intestinal motility can help with spasmodic gastrointestinal symptoms. These benefits must be weighed against urinary retention and constipation, which represent clinically important consequences of reducing smooth muscle activity too far.

Monitoring should compare improvement in the targeted condition with signs of excessive anticholinergic activity. Depending on the indication, clinicians may assess respiratory or bladder-related benefit, while watching for dry mouth, blurred vision, constipation, urinary retention, increased heart rate, and confusion. This approach is especially important when treating older adults, whom the overview identifies as more vulnerable to adverse effects.